EUCTR2013-000961-36-IT进行中（未招募）不适用
Tolerability and safety evaluation of the administration of Ig VENA at high infusion rates. Open label phase III study. - Ig VENA Infusion Speed
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Kedrion SpA
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for ID patients:
- •1. Patients with a diagnosis of primary or secondary hypo-gammaglobulinaemia or a-gammaglobulinaemia.
- •2. Males or females aged between 18 and 64 years (= 18 and = 64 years).
- •3. Patients in treatment with intravenous immunoglobulins for at least 6 months prior to study entry.
- •4. Written informed consent and consent to handle personal data by participating subjects or legal guardians.
- •Inclusion criteria for ITP patients:
- •1. Patients with a diagnosis of persistent ITP (3 to 12 months from diagnosis), chronic ITP (lasting for more than 12 months) and new diagnosis of ITP (from diagnosis to 3 months).
- •2. Males or females aged between 18 and 64 years (= 18 and = 64 years).
- •3. Patients who have made at least one previous treatment with immunoglobulin.
- •4. Baseline platelet count: <20x109/l
- •5. Written informed consent and consent to handle personal data by participating subjects or legal guardians.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria (ID Patient):
- •1. Patients who have not previously had therapy with immunoglobulins.
- •2. Positivity for HIV, HCV, HBV, risky behaviour for blood-transmitted viral infections such as drug abuse or risky sexual relations
- •3. Pregnant or breastfeeding women or women of childbearing age who do not use an adequate system of contraception.
- •4. Severe systemic conditions or associated conditions contraindicating the use of immunoglobulins such as severe thrombocytopenia, clotting disorders, known deficiency of one or more IgG subclasses, IgA deficit or presence of IgA antibodies, allergic reactions to immunoglobulins or the presence of a history of severe adverse reactions to blood or blood products.
- •5. Acute bacterial infections requiring treatment with intravenous antibiotics within 1 week from inclusion in the study
- •6. Kidney disorders characterised by proteinuria = 3.5 g/24hr, serum protein levels < 60 g/l or serum albumin levels < 30 g/l.
- •7. Chronic kidney disease or creatinine clearance < 80 ml/min in accordance with the Cockroft formula.
- •8. History of heart failure (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension, lymphoma, hypoalbuminaemia, protein-losing enteropathy (characterised levels of serum protein < 60 g/l and serum albumin < 30 g/l).
- •9. Positivity for thrombophilia test (homocysteine test).
- •10. Subjects will be excluded from the study in the presence of any condition that in the Investigator’s opinion may interfere with the evaluation of study results.
- •11. Subjects who had participated in a clinical trial with another product within one month (30 days) from enrolment or subjects who do not wish to give their consent to participate will be excluded from the study
- •Exclusion criteria (ITP Patients):
- •1. Patients who have not previously had therapy with immunoglobulins.
- •2. Positivity for HIV, HCV, HBV, risky behaviour for blood-transmitted viral infections such as drug abuse or risky sexual relations
- •3. Pregnant or breastfeeding women or women of childbearing age who do not use an adequate system of contraception.
- •4. Severe systemic conditions or associated conditions contraindicating the use of immunoglobulins, , known deficiency of one or more IgG subclasses, IgA deficit or presence of IgA antibodies, allergic reactions to immunoglobulins or hypersensitivity to any of the excipients, the presence of a history of severe adverse reactions to blood or blood products.
- •5. Kidney disorders characterized by proteinuria = 3,5 g/24 hr, serum protein levels < 60 g/l or serum albumin levels < 30 g/l.
- •6. Chronic kidney disease or creatinine clearance < 80 ml/min, in accordance with Cockroft formula.
- •7. History of heart failure (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension.
- •8. History of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within the last 12 month.
- •9. Subjects will be excluded from the study in the presence of any condition that in the Investigator’s opinion may interfere with the evaluation of study results.
- •10. Subjects who had participated in a clinical trial with another product within one month (30 days) from enrolment or subjects who do not wish to give their consent to participate will be excluded from the study.
研究者
相似试验
进行中（未招募）
1 期
See the full titleEUCTR2013-000961-36-DEKedrion SpA35
尚未招募
1 期
Assessment of the tolerance and safety of Prescription of different doses of Psilocybin in Healthy adults.F03.600depressionRBR-37qx63dBiocase Brasil
招募中
3 期
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)Alzheimer's DiseaseJPRN-jRCT2031220471Masaki Takeshi600
招募中
1 期
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of PLN-74809Respiratory - Other respiratory disorders / diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInflammatory and Immune System - Other inflammatory or immune system disordersPrimary Sclerosing CholangitisIdiopathic pulmonary fibrosisACTRN12620000536965Pliant Therapeutics, Inc.80
已完成
4 期
Study to Assess the Effectiveness and Safety of Dhathri Fair Skin Cream in Skin Fairness, Black Spots and Dark Circles.CTRI/2013/05/003683Dhathri Ayurveda Private Limited36